ArticleCartilage2026
Safety and Efficacy of Allogeneic Integrin α10β1-Selected Mesenchymal Stem Cells in the Treatment of Knee Osteoarthritis: A First-In-Human Phase I/IIa Dose Escalation Study.
Article in Cartilage, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PurposeSafety and efficacy of allogeneic integrin α10β1-selected MSCs (integrin α10-MSCs) have been shown in two post-traumatic osteoarthritis (OA) equine models. The aim of this study is to evaluate safety, tolerability and preliminary efficacy of allogeneic integrin α10-MSCs in human symptomatic knee OA.MethodsIn a first-in-human prospective multicentre phase I/IIa dose escalation study, 24 patients (41-75 years, Kellgren-Lawrence grade II-III knee OA) were treated with a single intra-articular injection of 4, 8 or 16 million integrin α10-MSCs. Safety and tolerability were assessed by adverse events, electrocardiography, vital signs, and physical and laboratory examinations. Clinical outcome was measured by visual analogue scale (VAS) for pain and Knee injury and Osteoarthritis Outcome Score (KOOS). Structural outcomes were assessed by X-ray and MRI. The total follow-up period was 24 months for the highest dose and 18 months for the lower doses.ResultsThe most frequently reported study drug-related adverse events were injection site pain, joint swelling and injection site movement impairment. All doses showed sustained improvements in pain and function, whereas the 16 million dose cohort showed earlier effects. The 16 million dose cohort also showed a reduction in bone marrow lesions, signs of an improved cartilage quality by T2* relaxation time, and a stable medial minimum joint space width.ConclusionsThis study demonstrated safety and efficacy of intra-articular injection of integrin α10-MSCs for the treatment of mild to moderate knee OA. At a dose of 16 million integrin α10-MSCs, a potentially quick and long-lasting therapeutic effect, supportive of disease-modification, was evident.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.